We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BioNTech and Fosun Pharma Begin Phase 2 COVID-19 Vaccine Trial in China
BioNTech and Fosun Pharma Begin Phase 2 COVID-19 Vaccine Trial in China
German drugmaker BioNTech and China’s Fosun Pharmaceutical Group have announced that the Pfizer/BioNTech COVID-19 vaccine candidate, BNT162b2, will be evaluated in a phase 2 study in China, building on an agreement the companies signed in March.